Physician profile
Alissa Fletcher
NPI 1215676291
$2,742.09
in general payments reported to CMS, 2019-2025
40 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $308 · 2023: $849 · 2024: $1,417 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.03 |
| Education | $316.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $435.46 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $408.82 | 2023-2025 | |
| Daiichi Sankyo INC. | $250.89 | 2022-2024 | Enhertu, Injectafer, Vanflyta |
| Seagen INC. | $163.24 | 2022-2023 | Padcev, Adcetris |
| Merck Sharp & Dohme LLC | $123.78 | 2023-2025 | Keytruda, Welireg |
| Genzyme Corporation | $110.12 | 2022-2024 | |
| Genentech USA, INC. | $99.63 | 2022-2024 | Polivy, Venclexta |
| Janssen Biotech, INC. | $93.75 | 2023-2024 | Talvey, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $79.76 | 2023-2024 | Imfinzi, Calquence, Enhertu |
| Celgene Corporation | $76.93 | 2023-2024 | Reblozyl, Opdualag |
| Avanos Medical | $73.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.32 | 2023-2025 | Fruzaqla, Vpriv |
| Abbvie INC. | $60.83 | 2024-2025 | |
| Exelixis INC. | $48.52 | 2024 | Cabometyx |
| Eisai INC. | $42.25 | 2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alissa Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.